LivingGLP1
parallel randomized trial

S003430

Design

Randomized
120
Start year
Treatment
6 weeks, follow-up 6 weeks
Countries
Sponsor
(not reported)
Eligibility
major depressive disorder by DSM-5; BMI 27 or higher; HDRS above 20

Conduct and analysis

Blinding
double blind
Sequence generation
not reported
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
Missing data

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1Liraglutide 3.0 mg subcutaneous once daily
Liraglutide 3.0 mg/day plus escitalopram
escitalopram 20 mg once daily; lifestyle: not reported
A2Placebo
Placebo plus escitalopram
escitalopram 20 mg once daily; lifestyle: not reported

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticLiraglutide 3.0 mg subcutaneous once daily
A1
Placebo
A2
Whole trial
ALL
agemean (years)41.2
agesd (years)12.6
bmimean (kg/m2)33.9
bmisd (kg/m2)11.8
femalepercent60

Results

2 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Percent body weight change (2 lines; O10)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
6A1percent change-3.2 percent1.0not stated; other; R0042455:p1
6A2percent change-0.2 percent0.1not stated; other; R0042455:p1